Shareholder Investigation of Tyme Technologies
Tyme Technologies Inc. (TYME) Accused of Distorting Data According to the complaint, Tyme is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives for metastatic pancreatic cancer and biomarker-recurrent